🟢 HELP is trading 5.15% up today after closing a $50M offering for Phase 3 trials

HELP is trading 5.15% up at $6.33 after Cybin/Helus Pharma closed a $50 million share offering to fund late-stage depression-trial work.

• The capital injection is earmarked for the company's Phase 3 pipeline, specifically focusing on late-stage depression treatments.
• The stock is seeing continued follow-through buying from the initial financing news on June 25, 2026, rather than a new catalyst.
• The move appears company-specific as the stock is outperforming broader markets, which are currently trading modestly lower.